

PRINTER RUSH

(PTO ASSISTANCE)

Application :	<u>09/643458</u>	Examiner :	<u>Housel</u>	GAU :	<u>1648</u>
From :	<u>he</u>	Location :	<u>IDC</u> FMF FDC	Date :	<u>7/12/05</u>
Tracking #:			<u>06025725</u>	Week Date: <u>10/18/04</u>	

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input type="checkbox"/> Other
<input type="checkbox"/> DRW	_____	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input checked="" type="checkbox"/> SPEC	_____	

[RUSH] MESSAGE: Table 2 on pg. 18, Table 4 on pg. 20, Table 5 on pg. 21, Table 6 on pg. 22, Table 7 on pgs. 23 + 24 and Table 10 on pg. 27 all have footnotes referring to "bolded" data. It is very hard to tell where the bolded data is. Please advise.

Thank you.

[XRUSH] RESPONSE: nothing is "bolded" in Table 10.

corrected

Bold text is bracketed

See Attachments

INITIALS: KP

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.
REV 10/04

SCHERING-PLOUGH CORPORATION
LAW DEPARTMENT
2000 GALLOPING HILL ROAD
K-6-1, MAIL STOP
KENILWORTH, NEW JERSEY 07033
(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

To:
Mrs. Kay Pinkney
Publications Branch, USPTO

FAX NUMBER:
~~1-703-308-6642~~
703-746-4272

FROM:
Immac J. Thampoe

PHONE NUMBER:
908-298-4080

TOTAL NO. OF PAGES INCLUDING COVER
7

DATE
July 21, 2005

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Fideliz Romero at 908-298-4080.

Application No.: 09/643,458

Filing Date: 08/22/2000

In Re Application of Mytych *et al.*

Group Art Unit: 1648


For: **METHODS AND REAGENTS FOR THE DETECTION OF
ANTIBODIES TO ADENOVIRUS**
Attorney Docket No. JB0976Q US

Dear Mrs. Pinkney:

Per your request, we have attached for printing purposes, Tables 2, 4, 5, 6, and 7 of the above identified application, wherein the bolded text referred to in the footnotes have been bracketed.

Thank you for your assistance in this matter. Please do not hesitate to contact me, should you have any questions.

Sincerely,


IMMAC J. THAMPOE
Reg. No.: 36,322

PHONE: (908)298-3955

FAX: (908)298-5388

09/643458

Table 2. Antiserum Reactivity to Immunized Peptides from Pig, Rat, and Rabbit Immunized with Ad5

Animal I.D.	Timepoint	Peptide:	Biosensor results in Response units (RU)						
			HVR1	HVR2	HVR3	HVR4	HVR5	HVR6	HVR7
Pig									
Ozzle									
Ozzle (6 months post)	Pre post		³ [456]	⁴ [208] [141]	³	³ [578]	³ [212]	³ [143]	⁴ [205]
RAT									
Normal rat serum (NRS)	NRS		47	44	76	46	60.5	36	34
Pooled rat serum from six rats (12 month post)	post		[456]	25	105	[357]	24	[87]	[215]
RABBIT									
Normal rabbit serum (NRBS)	NRBS		9	7.5	ND	6.8	5.5	ND	ND
Rabbit 504 (17 months post)	post		[754]	46	115	[204]	47	92	[636]

pre = pre-dosed sample
 post = post-dosed sample
 ND = Not Determined
 D = Day after dosing
 * Although there is no data for NRBS, the sample was considered positive due to strong reactivity.

Positive results are indicated in **Bold** based on the following ratio:
 RU of post sample / RU of pre, NRS or NRBS sample ≥ 2.0

09/643458

Table 4. Reactivity of Commercial Type-Specific Adenovirus Antibodies to Immobilized Peptides

Vendor	Ab Specificity	Sample I.D.	Peptide:	Biosensor results in Response						
				units (RU)						
				HVR1	HVR2	HVR3	HVR4	HVR5	HVR6	HVR7
Biogenesis	Goat anti-Ad2 hexon	post		25	3	17	3	5	15	15
Accurate	Murine anti-Ad penton (85 KD)	post		0	0	0	0	0	0	0
Biodesign	Goat anti-Ad2 hexon	post		30	10	ND	8	13	ND	ND
Biospecific	anti-Ad6	post		ND	ND	16	ND	ND	10	13
Biospecific	anti-Ad3	post		ND	ND	0	ND	ND	0	0
Lee Biol.	Rabbit anti-Ad5	pre post		0 [255]	0 0	0 6	0 0	0 0	0 8	0 10

20

pre = pre-dosed sample
post = post-dosed sample
ND = Not Determined

Positive results are indicated in **Bold** based on the following criteria:

- 1) Ratio of RU of post sample / RU of pre sample ≥ 2.0 OR
- 2) Post sample (without pre) with a binding greater than 50 RU

09/643458

21

Table 5. Reactivity of Pre-Clinical Serum Samples to Immobilized Peptides from Pigs that Received rAd5

Sample I.D.	Timepoint	Peptide:	Biosensor results in Response units (RU)						
			HVR1	HVR2	HVR3	HVR4	HVR5	HVR6	HVR7
377	pre		56	46	101	39	41	67	139
5	D15		[1085]	59	112	79	58	106	151
384	pre		73	71	99	52	57	98	129
8	D15		[795]	57	87	[131]	51	70	102
8	D29		[820]	65	81	[111]	62	71	101
393	pre		96	189	83	83	100	65	80
12	D15		[483]	127	71	140	57	95	72
12	D28		[1460]	107	92	[201]	63	104	99
12	D48		[685]	113	107	[177]	94	86	91
389	pre		48	45	73	34	48	69	87
11	D15		[729]	39	52	32	50	53	64
11	D28		[1484]	61	62	[125]	88	58	80
11	D48		[1024]	68	61	[136]	65	54	84
380	pre		72	80	74	77	73	60	94
7	D15		[936]	64	70	62	56	60	81
7	D28		[1200]	66	69	75	80	58	76
385	pre		[107]	80	85	62	72	59	81
3	D15		[567]	49	41	41	42	40	55

pre = pre-dose sample

D = Day after dosing

Positive results are indicated in Bold based on the following ratio:
RU of post sample / RU of pre sample \geq 2.0

09/643458

Table 6. Reactivity of Serum Samples to Immobilized Peptides from Patients with Non-Small Cell Lung Cancer Administered IAC5

Patient Initials	Timepoint	Peptide:	Biosensor results in Response units (RU)						
			HVR1	HVR2	HVR3	HVR4	HVR5	HVR6	HVR7
ER	PRE		19	19	36	14	22	22	28
	D7		ND	ND	ND	ND	ND	ND	ND
	D14		26	27	41	21	29	24	31
	D21		21	22	37	17	18	21	27
	PRE		24	27	50	25	28	73	30
FH	D3		21	21	ND	20	16	ND	ND
	D7		388	17	ND	27	23	ND	ND
	D14		1161	34	55	34	37	83	32
	D21		945	33	48	29	34	68	25
	PRE		24	20	37	12	28	17	21
IK	D7		2045	14	ND	42	15	ND	ND
	D14		8266	25	37	101	25	17	21
	D21		7549	13	ND	161	9	ND	ND
	D28		8385	29	39	87	37	18	23
	2MO.		2796	10	ND	18	9	ND	ND
HH	PRE		33	20	61	19	22	38	51
	D3		30	13	ND	13	5	ND	ND
	D7		60	22	ND	22	18	ND	ND
	D14		660	23	45	17	16	28	43
	D21		688	22	ND	15	9	ND	ND
MK	D28		433	25	41	18	20	27	38
	2MO.		170	15	ND	9	5	ND	ND
	PRE		11	14	28	13	11	15	13
	D3		ND	ND	ND	ND	ND	ND	ND
	D7		14	18	29	16	16	16	14
SM	PRE		23	23	37	16	32	16	1230
	D6		108	20	40	14	27	20	1026
	D27		173	12	29	9	21	19	523
	D48		151	7	ND	4	11	ND	ND

D = Day after dosing
 ND = Not Determined
 pre = pre-dose
 MO. = Month's after dosing
 Positive results are indicated in Bold based on the following ratio:
 RU of post sample / RU of pre sample \geq 2.0

09/643458

23

Table 7. Reactivity of Clinical Samples to Immobilized Peptide from Patients Administered rAd5

A. Patients with Recurrent & Malignant Head and Neck Cancer

Patient Initials	Timepoint	Peptide:	HVR1	HVR3	HVR4	HVR7
TGL	PRE		11	32	17	15
	D3		9	24	12	12
	D8		10	29	14	13
	D15		9	27	14	13
	D22		11	31	16	16
	D28		11	29	16	17
RWT	PRE		53	59	27	32
	D3		47	50	23	28
	D10		58	52	28	36
	D14		42	35	17	23

B. Patient with Recurrent Melanoma & Breast Cancer

Patient Initials	Timepoint	Peptide:	HVR1	HVR3	HVR4	HVR7
ES	PRE		27	27	24	20
	D3		23	26	20	18
	D7		54	27	23	19
	D14		252	28	22	19
	D21		185	28	21	18
	D28		79	15	10	8

C. Patient with Peritoneal Carcinomatosis

Patient Initials	Timepoint	Peptide:	HVR1	HVR3	HVR4	HVR7
VKA	PRE		7	35	16	12
	D2		10	33	17	16
	D3		8	30	13	17
	D7		14	49	26	17
	D14		41	36	16	29
	D21		45	44	25	26
	D28		38	31	16	25

09/64 3458

24

D. Patients with Hepatocellular Carcinoma

Patient Initials	Timepoint	Peptide:	HVR1	HVR3	HVR4	HVR7
JT	PRE		50	206	40	132
	D2		10	33	17	16
	D3		25	136	18	85
	D7		1629	109	27	73
	D14		7538	171	108	111
	D21		5208	187	102	116
	D28		3837	174	83	108
WMF	PRE		17	24	20	16
	D3		17	23	20	18
	D7		68	18	17	15
	D14		163	27	22	21
DFB	D28		106	19	18	19
	PRE		12	21	13	14
	D3		14	20	14	18
	D7		49	15	12	16
	D14		1226	26	14	19
	D21		606	22	10	14
	D28		414	32	19	23
RK	PRE		21	21	14	19
	D3		19	18	12	19
	D7		40	25	20	25
	D14		113	21	15	18
	D21		75	19	13	19
	D28		88	32	22	32

PRE = pre-dose

D = Day after dosing

Positive results are indicated in Bold based on the following ratio:

RU of post sample / RU of pre sample ≥ 2.0